Portal de Periódicos da CAPES

Dried blood spot sampling for quantitative bioanalysis: time for a revolution?

2010; Future Science Ltd; Volume: 2; Issue: 11 Linguagem: Inglês

10.4155/bio.10.153

1757-6199

Neil Spooner,

Clostridium difficile and Clostridium perfringens research

BioanalysisVol. 2, No. 11 Special Focus: Dried Blood Spots - ForewordFree AccessDried blood spot sampling for quantitative bioanalysis: time for a revolution?Neil SpoonerNeil SpoonerPlatform Technologies & Science Drug Metabolism & Pharmacokinetics, GlaxoSmithKline Research & Development, Ware, Hertfordshire, SG12 0DP, UK. Published Online:20 Oct 2010https://doi.org/10.4155/bio.10.153AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail Well here we are again! Following hot on the heels of the special focus issue of Bioanalysis dedicated to dried blood spots in August 2010, we have another special issue concentrating on the same subject. The large volume of high-quality contributions in these two editions and the numerous dedicated conference sessions and workshops on this subject in the last 2 years is rapidly contributing to a broader understanding and acceptance of this technique by the drug bioanalysis community. However, the work of this community is increasingly highly regulated, which naturally leads to a conservative approach and in-depth questioning of any new technologies. This is resulting in a number of members of the community holding back on implementing any real change, whilst they wait for others to trip up, or for the regulators to make a proclamation etched in stone about the suitability of the technique. Whilst this may at times be 'irritating' to the leaders who just want to get out there and do it – "isn't it obvious?" – this is an understandable reaction that must be heard. We need to take the time to thoroughly understand the technique and to perform the best science possible. However, it is my belief that we should not let all the understandable questions and reservations bury the pure fact that there are real benefits to be had with this technique. Standing still is not an option. The pressure from society to deliver ethical and environmentally friendly solutions is ever present. Added to this is the need of the pharmaceutical industry and healthcare providers to get better value for their money. Dried blood spot sampling delivers on all these aspects in spades and so will become an accepted part of the drug-development landscape of the future. The revolution is here!Anyway, enough of my rant! I welcome you to this special focus issue of Bioanalysis dedicated to dried blood spot sampling. I would like to thank the authors for sharing with us their high-quality science and discussion. I would also like to thank the dedicated and hard work of the editorial staff for putting together this special issue.Financial & competing interests disclosureThe author is an employee of GlaxoSmithKline (GSK) Research and Development and is eligible for GSK stock options and has stock ownership. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.FiguresReferencesRelatedDetailsCited ByA concise review on analytical profile of risperidone15 May 2022 | Current Trends in Pharmacy and Pharmaceutical Chemistry, Vol. 4, No. 2A concise review on analytical profile of chlorthalidone4 March 2022 | Research Journal of Pharmaceutical Dosage Forms and TechnologyGiving patients choices: AstraZeneca's evolving approach to patient-centric samplingChristopher Bailey, Cecilia Arfvidsson, Lynsey Woodford & Miné de Kock27 July 2020 | Bioanalysis, Vol. 12, No. 13Microsampling for quantitative bioanalysis, an industry update: output from an AAPS/EBF surveyShefali R Patel, Peter Bryan, Neil Spooner, Philip Timmerman & Enaksha Wickremsinhe11 April 2019 | Bioanalysis, Vol. 11, No. 7Validation, quality control, and compliance practice for mass spectrometry assays in the clinical laboratoryPotential missing steps for a wide use of dried matrix spots in biomedical analysisJulien Déglon, Luc Alexis Leuthold & Aurélien Thomas17 September 2015 | Bioanalysis, Vol. 7, No. 18Novel membrane devices and their potential utility in blood sample collection prior to analysis of dried plasma spotsRobert Sturm, Jack Henion, Richard Abbott & Phil Wang1 September 2015 | Bioanalysis, Vol. 7, No. 16Applying dried blood spot sampling with LCMS quantification in the clinical development phase of tasquinimodLeif D Svensson, Carl-Johan Sennbro, Camilla Svanström & Gunnar P Hansson14 January 2015 | Bioanalysis, Vol. 7, No. 2Interpatient distributions of bloodspot area per fixed volume of application: Comparison between filter paper and non-cellulose dried matrix spotting cardsClinica Chimica Acta, Vol. 437Applications and Chemistry of Cellulose Papers for Dried Blood Spots13 June 2014Pharmaceutical Perspectives of Use of Dried Blood Spots13 June 2014First experience with a fully automated extraction system for simultaneous on-line direct tandem mass spectrometric analysis of amino acids and (acyl-)carnitines in a newborn screening setting10 March 2014 | Rapid Communications in Mass Spectrometry, Vol. 28, No. 8About sound science, stable isotope dilution, blasphemy and heresyLeif D Svensson13 August 2013 | Bioanalysis, Vol. 5, No. 16Pharmaceutical toxicology: Designing studies to reduce animal use, while maximizing human translationRegulatory Toxicology and Pharmacology, Vol. 66, No. 1A dried blood spot update: still an important bioanalytical technique?Neil Spooner16 April 2013 | Bioanalysis, Vol. 5, No. 8Recent development in software and automation tools for high-throughput discovery bioanalysisWilson Z Shou & Jun Zhang21 May 2012 | Bioanalysis, Vol. 4, No. 9Development of an UPLC–MS/MS method for the determination of antibiotic ertapenem on dried blood spotsJournal of Pharmaceutical and Biomedical Analysis, Vol. 61Conference Report: The 19th International Reid Bioanalytical ForumHoward Hill20 December 2011 | Bioanalysis, Vol. 3, No. 24Dried blood spots as a sampling technique for the quantitative determination of guanfacine in clinical studiesYuanyuan Li, Jack Henion, Richard Abbott & Phillip Wang28 November 2011 | Bioanalysis, Vol. 3, No. 22Utilization of DBS within drug discovery: a simple 2D-LC–MS/MS system to minimize blood- and paper-based matrix effects from FTA elute™ DBSGraeme T Clark & Julian J Haynes7 June 2011 | Bioanalysis, Vol. 3, No. 11 Vol. 2, No. 11 STAY CONNECTED Metrics History Published online 20 October 2010 Published in print November 2010 Information© Future Science LtdFinancial & competing interests disclosureThe author is an employee of GlaxoSmithKline (GSK) Research and Development and is eligible for GSK stock options and has stock ownership. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download